Ischemia-modified albumin and NT-prohormone-brain natriuretic peptide in peripheral arterial disease

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 2, 2006, Pages 207-212

  Montagnana, Martina ^a   Lippi, Giuseppe ^a,c   Fava, Cristiano ^b   Minuz, Pietro ^b   Santonastaso, Clara Lechi ^a   Arosio, Enrico ^b   Guidi, Gian Cesare ^a  

^a Istituto di Chimica e Microscopia Clinica   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Heart failure; Ischemia modified albumin; Myocardial ischemia; Natriuretic peptides; Peripheral arterial disease

Indexed keywords

ALBUMINOID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HORMONE PRECURSOR; ISCHEMIA MODIFIED ALBUMIN; TROPONIN T; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SYMPTOM; THORAX PAIN;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERIPHERAL VASCULAR DISEASES; SERUM ALBUMIN;

EID: 32544452552     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2006.038     Document Type: Article

References (39)

1. Jacoby DS, Mohler ER. Peripheral arterial disease. Risk factor identification and modification. In: Abela GS, editor. Peripheral vascular disease. Basic diagnostic and therapeutic approaches. Philadelphia, PA: Lippincott Williams & Wilkins, 2004:190-7.
2. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
3. Cimminiello C. PAD. Epidemiology and pathophysiology. Thromb Res 2002;106:V295-301.
4. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004;109:733-9.
5. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et al. Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884-92.
6. Ng LL, Loke IW, Davies JE, Geeranavar S, Khunti K, Stone MA, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol 2005;45:1043-50.
7. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003;17:1105-7.
8. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-Terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75.
9. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003;108:2987-92.
10. Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N-terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 2000;84:421-4.
11. Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond) 1995;88:551-6.
12. Omland T. Clinical and laboratory diagnostics of cardiovascular disease: focus on natriuretic peptides and cardiac ischemia. Scand J Clin Lab Invest Suppl 2005;240:18-24.
13. Roy D, Quiles J, Sharma R, Sinha M, Avanzas P, Gaze D, et al. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise induced skeletal muscle ischemia. Clin Chem 2004;50:1656-60.
14. Gidenne S, Ceppa F, Fontan E, Perrier F, Burnat P. Analytical performance of the Albumin Cobalt Binding (ACB) test on the Cobas MIRA Plus analyzer. Clin Chem Lab Med 2004;42:455-61.
15. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, et al. Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001;47:464-70.
16. McCord J. Oxygen-derived free radicals in post ischemic tissue injury. N Engl J Med 1985;312:159-63.
17. Cobbe SM, Poole-Wilson PA. The time of onset and severity of acidosis in the myocardial ischemia. J Mol Cell Biol 1980;12:745-60.
18. Anwaruddin S, Jannuzzi JL, Baggish AL, Lewandrowski L, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 2005;123:140-45.
19. Salvagno GL, Lippi G, Montagnana M, Schena F, Ballestrieri F, Guidi GC. Influence of physical exercise on the preanalytical variability of pro-BNP and IMA. Clin Chem Lab Med 2005;9:A126.
20. Hackam DG. Cardiovascular risk prevention in peripheral arterial disease. J Vasc Surg 2005;41:1070-3.
21. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
22. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N-terminal proB-type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004;6:365-8.
23. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004;29:439-93.
24. Vainas T, Stassen FR, de Graaf R, Twiss EL, Herngreen SB, Welten RJ, et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg 2005;42:243-51.
25. Svensson P, de Faire U, Niklasson U, Hansson LO, Ostergren J. Plasma NT-proBNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. Blood Press 2005;14:99-106.
26. Diehm C, Kareem S, Lawall H. Epidemiology of peripheral arterial disease. Vasa 2004;33:183-9.
27. Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis HW Jr. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005;41:816-22.
28. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993;88:837-45.
29. Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br Med J 1996;313:1440-4.
30. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999;19:538-45.
31. Park H, Das M, Aronow WS, McClung JA, Belkin RN. Relation of decreased ankle-brachial index to prevalence of atherosclerotic risk factors, coronary artery disease, aortic valve calcium, and mitral annular calcium. Am J Cardiol 2005;95:1005-6.
32. Kelly R, Staines A, MacWalter R, Stonebridge P, Tunstall-Pedoe H, Struthers AD. The prevalence of treatable left ventricular systolic dysfunction in patients who present with non cardiac vascular episodes: a case control study. J Am Coll Cardiol 2002;39:219-24.
33. Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995;92:1558-64.
34. Steg PG, Joubin L, McCord J, Abraham WT, Hollander JE, Omland T, et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 2005;128:21-9.
35. Arat-Ozkan A, Kaya A, Yigit Z, Balci H, Okcun B, Yazicioglu N, et al. Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. Echocardiography 2005;22:473-8.
36. Kikuta K, Yasue H, Yoshimura M, Morita E, Sumida H, Kato H, et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 1996;132:101-7.
37. Aslan D, Apple FS. Ischemia modified albumin: clinical and analytical update. Lab Med 2004;35:1-5.
38. Troxler M, Thompson D, Homer-Vanniasinkam S. Ischaemic skeletal muscle increases serum ischaemia modified albumin. Eur J Vasc Endovasc Surg 2005. In press (doi:10.1016/j.ejvs.2005.06.019).
39. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski, JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003;107:2403-5.